Uropathogenic E. coli's multidrug resistance has become a potential threat to global health. The purpose of the current study is to evaluate the antimicrobial against Extended Spectrum -Lactamases (ESBL) and AmpC producer E. coli isolates. Methodology: All clinical isolates of Escherichia coli, isolated from UTI patients were evaluated for susceptibility to a panel of antimicrobials and were analysed for the ESBL and AmpC using Vitek 2. Results and conclusions: Total 1911 no of urine samples were screened out of these 782 were having the significant bacteriuria. In this 226 sample have shown the growth of E.Coli. Maximum no of patients are of age group more than 60 years (35.41%).52.21% were ESBL producers. The AST of ESBL E.Coli showed isolates were sensitive to Tigecycline (100%) and were 99.15% sensitive to Imipenem and Meropenem followed by 97.46% to Amikacin. The 37 no wee identified the AmpC. Further research is required to detect ESBL and AmpC enzyme production simultaneously in such isolates. It is necessary to detect ESBL and AmpC-producing E. coli early to prevent treatment failure. Continuous surveillance and prudent antibiotic use, as well as the implementation of effective infection control measures, are essential